Last reviewed · How we verify
IMP4297
At a glance
| Generic name | IMP4297 |
|---|---|
| Sponsor | Impact Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer (PHASE3)
- Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer (PHASE2)
- A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects (PHASE1)
- An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition (PHASE1)
- An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition (PHASE1)
- IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer (PHASE1, PHASE2)
- A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors (PHASE1, PHASE2)
- JS001+IMP4297 in Patients With Advanced Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMP4297 CI brief — competitive landscape report
- IMP4297 updates RSS · CI watch RSS
- Impact Therapeutics, Inc. portfolio CI